Galderma announces Mirvaso gel pump dispenser for treating rosacea

Galderma Laboratories recently announced that a new pump dispenser design for Mirvaso topical gel, 0.33% is available to treat persistent erythema associated with rosacea in adults.

Mirvaso (brimonidine) topical gel, 0.33% is an alpha adrenergic agonist. The Mirvaso Gel Pump is available by prescription in U.S. pharmacies, according to a press release. The pump’s delivery system dispenses a consistent dose at each use.

“The availability of the Mirvaso gel pump offers a number of benefits to patients with facial erythema,” Sandra Johnson, MD, FAAD, dermatologist at Johnson Dermatology in Fort Smith, Arkansas, and Galderma consultant, stated in the release. “Research proves that the majority of patients prefer a pump dispenser over a tube. … I am excited for the introduction of this dosing option that is convenient to use for my patients.”

Erythema is a common symptom of rosacea, affecting up to 93% of patients with the disease, according to the release.

Mirvaso gel was approved by the FDA in 2013, and is the only FDA-approved medication for treating persistent facial redness of rosacea, according to the release. It is used once daily, and can reduce redness for up to 12 hours, Galderma reported.

Adverse events of Mirvaso topical gel, 0.33% reported in clinical trials included erythema, flushing, skin burning sensation and contact dermatitis, according to the release.

Reference: www.galdermausa.com